Bridgeway Capital Management LLC Has $221,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Bridgeway Capital Management LLC trimmed its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 67.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,300 shares of the company's stock after selling 86,000 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.06% of Corvus Pharmaceuticals worth $221,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in CRVS. Virtus ETF Advisers LLC acquired a new position in Corvus Pharmaceuticals during the 4th quarter worth approximately $47,000. PKS Advisory Services LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $56,000. Alpine Global Management LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $62,000. ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $72,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth approximately $73,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Stock Down 8.6%

CRVS opened at $4.05 on Tuesday. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.75 and a twelve month high of $10.00. The company has a fifty day moving average of $3.61 and a 200-day moving average of $5.43. The stock has a market cap of $276.08 million, a PE ratio of -4.35 and a beta of 0.67.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Sell-side analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CRVS. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. StockNews.com raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday. Finally, Oppenheimer reissued an "outperform" rating and set a $17.00 target price (up from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $16.33.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.